Investigating regenerative potential of retinal cells

Article

Investigators from The Scripps Research Institute, and Thomas Reh, PhD from the University of Washington, received the highest possible scores for their proposal to investigate the regenerative potential of retinal cells, resulting in a $4.66 million NIH Transformative Award.

Zhang and co-principal investigators Sheng Ding, PhD, from The Scripps Research Institute, and Thomas Reh, PhD from the University of Washington, received the highest possible scores for their proposal to investigate the regenerative potential of retinal cells, resulting in a $4.66 million NIH Transformative Award. Their long-term goal is to restore visual function lost through diseases such as macular degeneration and retinitis pigmentosa.

“The success of this work could mean a paradigm shift in how retinal disease is treated, and could have broad and profound impact on human disease therapies by utilizing the regenerative power of our own cells,” said Zhang.

Some vertebrates, such as goldfish and newts, have a remarkable ability to regenerate a lost limb or eye - something it was thought no mammal can do. However, they recently showed proof of principle at a small-scale level in mice by turning Muller cells into a type of retinal neuron.

“The human genome is quite similar to that of a newt, but we humans seem to have lost the potential to regenerate our own cells, possibly due to some inhibitory mechanims,” Zhang said. “We are seeking small molecule chemicals that can block these inhibitions and consequently unlock humans' regenerative potential.”

The researchers are looking at particular kinds of cells called Muller cells, which are abundant and have the ability to regenerate nerve cells after retinal injury in fish, they usually play a supporting role in the central nervous system neurons of humans, such as those present in the eye or brain. This study proposes to use chemicals to turn Muller cells into photoreceptors in the eye - cells that are lost in two diseases that are leading causes of blindness, macular degeneration and retinitis pigmentosa.

Identification of chemicals for Muller cells reprogramming and differentiation will provide new avenues in developing cell-based therapy as well as small molecule drugs for regenerative medicine, and facilitate new understanding of the mechanisms of trans-differentiation, according to the scientists. They plan to screen more than 100,000 compounds in order to identify the chemicals that prompt mouse Muller glia to develop new neurons, conferring the power of regeneration to the mammalian retina.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
© 2025 MJH Life Sciences

All rights reserved.